Apolipoprotein E polymorphism, serum lipids, myocardial infarction and severity of angiographically verified coronary artery disease in men and women

Lehtinen, Saara; Lehtimäki, Terho; Sisto, Tero; Salenius, Juha-Pekka; Nikkilä, Matti; Jokela, Hannu; Koivula, Timo; Ebeling, Freja; Ehnholm, Christian

doi:10.1016/0021-9150(94)05469-y

Cited by 116 publications

(74 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of the E4-containing phenotypes was significantly higher in cardiovascular and cerebrovascular ailments such as myocardial infarction, hypertension, coronary heart disease and stroke etc [25]. Mendes-Lana A demonstrated that the presence of Apo E2 can confer a protective effect, the presence of Apo E4 implies an enhanced risk of dyslipidemia [26], and our results are in accordance with above studies for E 4 allele.…”

Section: Discussionsupporting

confidence: 91%

Apolipoprotein E Gene Polymorphism And Its Effect On Plasma Lipids In Arteriosclerosis

Zende

Bankar²,

Kamble³

et al. 2013

JCDR

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 91%

Apolipoprotein E Gene Polymorphism And Its Effect On Plasma Lipids In Arteriosclerosis

Zende

Bankar²,

Kamble³

et al. 2013

JCDR

View full text Add to dashboard Cite

“…22 These results have raised expectations that the ApoE polymorphism may be useful in identifying asymptomatic individuals who are at higher risk of CAD. However, we also point out that there have also been numerous studies that have found no associations, [23][24][25][26][27][28] or the relative frequency of the ⑀4 allele was actually lower in cases than in control subjects. 48 Other studies have found associations between the frequency of disease (CAD, IHD, and CHD) and the frequency of the ⑀2 allele in addition to an association with the frequency of the ⑀4 allele, 49,50 whereas 1 study only found an association between the presence of carotid artery disease and the presence of the ⑀2 allele.…”

Section: Association Of Cad With Apoe Genotypementioning

confidence: 56%

“…22 Although there is increasing evidence of ApoE as a CAD susceptibility gene, there have also been several studies that have reported no significant association between ApoE genotypes and risk of clinically defined symptomatic CAD. [23][24][25][26][27] Most ApoE genotype association studies have measured only the marginal, independent association between variation in ApoE genotype and variation in risk of CAD either before or after statistical adjustment for variation in other risk factors. The marginal effect of a genotype is a statistical measure of the impact of a particular genotype, averaged over all of the phenotypes in a particular sample that are associated with that particular genotype.…”

mentioning

confidence: 99%

The Relationship Between Risk Factor Levels and Presence of Coronary Artery Calcification is Dependent on Apolipoprotein E Genotype

Kardia

Haviland

Ferrell

et al. 1999

ATVB

View full text Add to dashboard Cite

Abstract-An important research question in the study of the genetics of coronary artery disease (CAD) is whether information about genetic variation will improve our ability to predict CAD beyond established risk factors. This question is especially relevant to the goal of identifying young, asymptomatic adults with coronary atherosclerosis who would benefit most from interventions to reduce risk. Coronary artery calcification (CAC) detected by electron-beam computed tomography is a relatively new method for detecting coronary atherosclerosis in asymptomatic individuals that has been shown to be a more accurate indicator of coronary atherosclerosis in asymptomatic individuals than other noninvasive techniques. In a study of asymptomatic women (nϭ169) and men (nϭ160) between the ages of 20 and 59 representative of the Rochester, Minnesota population, we used logistic regression to ask whether the most common Apolipoprotein (Apo) E genotypes (⑀3/2, ⑀3/3, and ⑀4/3) predict the presence of CAC. The addition of information about ApoE genotypes to logistic models containing each separate risk factor did not improve prediction of CAC (PϾ0.10 in both women and men). However, there was significant evidence (PϽ0.10) that associations between variation in the probability of having CAC and variation in body mass index, plasma total cholesterol, and plasma ApoB in men and body mass index, plasma triglycerides, plasma ApoA1, and plasma ApoE in women were dependent on ApoE genotype.

show abstract

“…6,8,10 The progression of coronary lesions is a strong predictor of coronary events, especially fatal events, 25 and the rupture of a vulnerable plaque often precedes occlusive coronary thrombosis and death. 26,27 The evidence for an association of ⑀4 with increased progression rate is weak, however, 28 -30 and we are not aware of studies investigating the association of apoE genotype and the occurrence of vulnerable plaques.…”

Section: Possible Reasons Why ⑀4 Specifically Associated With Risk Ofmentioning

confidence: 99%

The Apolipoprotein ε4 Allele Determines Prognosis and the Effect on Prognosis of Simvastatin in Survivors of Myocardial Infarction

et al. 2000

View full text Add to dashboard Cite

Background-Carriers of the ⑀4 allele of the apolipoprotein E gene are at a higher risk of coronary heart disease than individuals with other genotypes. We examined whether the risk of death or a major coronary event in survivors of myocardial infarction depended on apolipoprotein E genotype and whether the benefits of treatment with simvastatin differed between genotypes. Methods and Results-Cox proportional hazards models were used to analyze 5.5 years of follow-up data from 966 Danish and Finnish myocardial infarction survivors enrolled in the Scandinavian Simvastatin Survival Study. A total of 16% of the 166 ⑀4 carriers in the placebo group died compared with 9% of the 312 patients without the allele, which corresponds to a mortality risk ratio of 1.8 (95% confidence interval, 1.1 to 3.1). The risk ratio was unaffected by considerations of sex, age, concurrent angina, diabetes, smoking, and serum lipids in multivariate analyses. Simvastatin treatment reduced the mortality risk to 0.33 (95% confidence interval, 0.16 to 0.69) in ⑀4 carriers and to 0.66 (95% confidence interval, 0.35 to 1.24) in other patients (Pϭ0.23 for treatment by genotype interaction). Apolipoprotein E genotype did not predict the risk of a major coronary event.Baseline serum levels of lipoprotein(a) also predicted mortality risk and could be combined with ⑀4-carrier status to define 3 groups of patients with different prognoses and benefits from treatment. Conclusions-Myocardial infarction survivors with the ⑀4 allele have a nearly 2-fold increased risk of dying compared with other patients, and the excess mortality can be abolished by treatment with simvastatin. (Circulation.

show abstract

Apolipoprotein E polymorphism, serum lipids, myocardial infarction and severity of angiographically verified coronary artery disease in men and women

Cited by 116 publications

References 23 publications

Apolipoprotein E Gene Polymorphism And Its Effect On Plasma Lipids In Arteriosclerosis

Apolipoprotein E Gene Polymorphism And Its Effect On Plasma Lipids In Arteriosclerosis

The Relationship Between Risk Factor Levels and Presence of Coronary Artery Calcification is Dependent on Apolipoprotein E Genotype

The Apolipoprotein ε4 Allele Determines Prognosis and the Effect on Prognosis of Simvastatin in Survivors of Myocardial Infarction

Contact Info

Product

Resources

About